1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN

1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNa2A AND RIBAVIRIN H. Wedemeyer, E. Janczewska, M. Wlodzimierz, C. Stanciu, F. Habersetzer, V. Carreno, A.M. Di Bisceglie, C. Tanasescu, R. Flisiak, M. Romero-Gomez, A. Fich, C. Zemmour, A. Fournillier, P. Zerr, D. Agathon, H. He, J.-Y. Bonnefoy, G. Inchauspe, J.-M. Limacher. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; Department of Infectious Diseases, Medical University of Silesia, Chorzow, Department of Internal Medicine, Medical University of Silesia, Katowice, Poland; Gr. T. Popa University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania; Hepato-Digestive Unit, Strasbourg University Hospitals, Strasbourg, France; Foundation for the Study of Viral Hepatitis, Madrid, Spain; Hepatology, Saint Louis University Liver Center, Saint Louis, MO, USA; Internal Medicine Clinic, Colentina Clinical Hospital, Bucharest, Romania; Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland; Unit for the Clinical Management of Digestive Diseases and Ciberehd, Valme University Hospital, Sevilla, Spain; Department of Gastroenterlogy, Soroka Medical Center, Beersheba, Israel; TRANSGENE SA, Illkirch, TRANSGENE SA, Lyon, France E-mail: wedemeyer.heiner@mh-hannover.de